Vivo Capital
Latest statistics and disclosures from Vivo Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SLNO, GERN, HRMY, SVA, Flamel Technologies Sa, and represent 53.52% of Vivo Capital's stock portfolio.
- Added to shares of these 10 stocks: SVA (+$76M), ADVM (+$21M), DYN (+$17M), RGLS (+$14M), SLN (+$13M), GERN (+$10M), QTTB (+$6.3M), DCTH, ZLAB, DTIL.
- Started 5 new stock positions in DTIL, ADVM, QTTB, RGLS, SVA.
- Reduced shares in these 10 stocks: Gracell Biotechnologies (-$96M), TARS (-$44M), Icosavax (-$27M), Alpine Immune Sciences (-$12M), APGE (-$11M), KALV (-$11M), VRNA (-$10M), PHVS (-$8.0M), Rayzebio (-$6.9M), IOVA (-$5.3M).
- Sold out of its positions in APGE, ARWR, Gracell Biotechnologies, Homology Medicines, Icosavax, IOVA, KALV, Precision Biosciences Ord, Rayzebio, PHVS.
- Vivo Capital was a net seller of stock by $-77M.
- Vivo Capital has $1.3B in assets under management (AUM), dropping by 4.20%.
- Central Index Key (CIK): 0001674712
Tip: Access up to 7 years of quarterly data
Positions held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vivo Capital
Vivo Capital holds 42 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Soleno Therapeutics Common (SLNO) | 28.3 | $360M | 8.4M | 42.80 |
|
|
| Geron Corp Common (GERN) | 7.1 | $90M | +12% | 27M | 3.30 |
|
| Harmony Biosciences Holdings Common (HRMY) | 6.9 | $88M | 2.6M | 33.58 |
|
|
| Sinovac Biotech SHS (SVA) | 6.0 | $76M | NEW | 12M | 6.47 |
|
| Avadel Pharmaceuticals Adr | 5.3 | $67M | -3% | 4.0M | 16.89 |
|
| Verona Pharma Sponsored Ads (VRNA) | 4.6 | $58M | -15% | 3.6M | 16.09 |
|
| ALX Oncology Holdings Common (ALXO) | 3.7 | $47M | 4.2M | 11.15 |
|
|
| Dyne Therapeutics Common (DYN) | 3.6 | $46M | +57% | 1.6M | 28.39 |
|
| Terns Pharmaceuticals Common (TERN) | 3.4 | $44M | 6.7M | 6.56 |
|
|
| Astria Therapeutics Common (ATXS) | 2.6 | $33M | -6% | 2.3M | 14.07 |
|
| Viridian Therapeutics Common (VRDN) | 2.3 | $29M | 1.7M | 17.51 |
|
|
| Silence Therapeutics Ads (SLN) | 1.9 | $24M | +116% | 1.1M | 21.60 |
|
| Olema Pharmaceuticals Common (OLMA) | 1.7 | $21M | 1.9M | 11.32 |
|
|
| Adverum Biotechnologies Common (ADVM) | 1.7 | $21M | NEW | 1.5M | 14.14 |
|
| Alpine Immune Sciences Common | 1.6 | $21M | -36% | 521k | 39.95 |
|
| Tarsus Pharmaceuticals Common (TARS) | 1.6 | $21M | -68% | 566k | 36.35 |
|
| Verastem Common (VSTM) | 1.4 | $18M | 1.5M | 11.80 |
|
|
| Crinetics Pharmaceuticals Common (CRNX) | 1.3 | $16M | 350k | 46.81 |
|
|
| Cogent Biosciences Common (COGT) | 1.2 | $15M | 2.2M | 6.72 |
|
|
| Sera Prognostics Common (SERA) | 1.2 | $15M | 1.7M | 9.10 |
|
|
| Regulus Therapeutics Common (RGLS) | 1.1 | $14M | NEW | 5.0M | 2.88 |
|
| Tourmaline Bio Common (TRML) | 1.1 | $14M | 592k | 22.90 |
|
|
| Compass Pathway Sponsored Ads (CMPS) | 1.1 | $13M | 1.6M | 8.32 |
|
|
| Oric Pharmaceuticals Common (ORIC) | 0.9 | $12M | 850k | 13.75 |
|
|
| Engene Holdings Common (ENGN) | 0.9 | $12M | 679k | 16.95 |
|
|
| Genetron Holdings Ads | 0.9 | $11M | 2.7M | 4.03 |
|
|
| IO Biotech Common (IOBT) | 0.8 | $11M | 6.2M | 1.73 |
|
|
| Savara Common (SVRA) | 0.8 | $10M | 2.1M | 4.98 |
|
|
| Zai Lab Adr (ZLAB) | 0.7 | $8.5M | +29% | 531k | 16.02 |
|
| Delcath Systems Common (DCTH) | 0.6 | $8.0M | +94% | 1.7M | 4.77 |
|
| Rezolute Common (RZLT) | 0.6 | $7.1M | -13% | 2.8M | 2.55 |
|
| Compass Therapeutics Common (CMPX) | 0.6 | $7.0M | 3.6M | 1.98 |
|
|
| Instil Bio Common (TIL) | 0.5 | $6.7M | 624k | 10.80 |
|
|
| Q32 Bio Common (QTTB) | 0.5 | $6.3M | NEW | 370k | 17.04 |
|
| Bolt Therapeutics Common (BOLT) | 0.4 | $4.9M | 3.5M | 1.40 |
|
|
| Unicycive Therapeutics Common (UNCY) | 0.4 | $4.8M | 3.5M | 1.38 |
|
|
| Allakos Common (ALLK) | 0.3 | $3.8M | 3.0M | 1.26 |
|
|
| Aligos Therapeutics Common (ALGS) | 0.3 | $3.5M | 3.5M | 0.98 |
|
|
| DBV Technologies SA Sponsored Ads | 0.2 | $2.0M | 2.7M | 0.75 |
|
|
| Codexis Common (CDXS) | 0.1 | $1.4M | 388k | 3.49 |
|
|
| Aadi Bioscience Common (AADI) | 0.1 | $1.2M | 510k | 2.34 |
|
|
| Precision Biosciences Common (DTIL) | 0.0 | $63k | NEW | 4.7k | 13.56 |
|
Past Filings by Vivo Capital
SEC 13F filings are viewable for Vivo Capital going back to 2016
- Vivo Capital 2024 Q1 filed April 22, 2024
- Vivo Capital 2023 Q4 filed Feb. 7, 2024
- Vivo Capital 2023 Q3 filed Nov. 8, 2023
- Vivo Capital 2023 Q2 filed Aug. 14, 2023
- Vivo Capital 2023 Q1 filed May 15, 2023
- Vivo Capital 2022 Q4 filed Feb. 13, 2023
- Vivo Capital 2022 Q3 filed Nov. 14, 2022
- Vivo Capital 2022 Q2 filed Aug. 15, 2022
- Vivo Capital 2022 Q1 filed May 13, 2022
- Vivo Capital 2021 Q4 filed Feb. 11, 2022
- Vivo Capital 2021 Q3 filed Nov. 15, 2021
- Vivo Capital 2021 Q2 filed Aug. 16, 2021
- Vivo Capital 2021 Q1 filed May 17, 2021
- Vivo Capital 2020 Q4 filed Feb. 16, 2021
- Vivo Capital 2020 Q3 filed Nov. 13, 2020
- Vivo Capital 2020 Q2 restated filed Nov. 13, 2020